Board Meeting Details
The Board of Directors meeting was held on Monday, October 26, 2026, commencing at 8:30 PM and concluding at 10:00 PM.
Key Business Transacted
1. Financial Results Approval
The Board approved and took on record the Un-Audited Standalone and Consolidated Financial Results for the half year ended September 30, 2026. The results were reviewed by statutory auditors A Bafna & Associates (Firm Reg. No: 121901W).
2. Dividend Declaration
Declared first interim dividend for Financial Year 2026-27 of ₹0.50 (Fifty Paise) per share. The Record Date for determining entitlement of members is Friday, October 30, 2026.
3. Compliance Note
The Board took note of various compliances made during the quarter ended September 30, 2026.
Standalone Financial Performance (H1 FY27)
Income Statement Highlights (INR Lacs)
- Revenue From Operations: ₹5,956.91
- Other Income: ₹145.78
- Total Income: ₹6,102.69
- Total Expenses: ₹4,568.11
- Profit Before Tax: ₹1,534.58
- Current Tax: ₹375.00
- Net Profit for Period: ₹1,159.58
- Paid Up Equity Share Capital: ₹1,195.70 (Face Value: ₹10 each)
- Basic EPS (Not Annualized): ₹9.70
- Diluted EPS (Not Annualized): ₹9.70
Balance Sheet Position (as of September 30, 2026 vs March 31, 2026 in INR Lacs)
- Total Equity and Liabilities: ₹17,456.89 (vs ₹15,919.06)
- Shareholder's Funds: ₹10,759.25 (vs ₹9,535.82)
- Share Capital: ₹1,195.70 (vs ₹1,193.30)
- Reserves & Surplus: ₹9,563.55 (vs ₹8,342.52)
- Non-Current Liabilities: ₹3,441.76 (vs ₹772.37)
- Long-Term Borrowings: ₹3,340.36 (vs ₹670.98)
- Current Liabilities: ₹2,899.18 (vs ₹5,238.20)
- Total Assets: ₹17,456.89 (vs ₹15,919.06)
- Non-Current Assets: ₹5,960.10 (vs ₹4,913.17)
- Current Assets: ₹11,496.79 (vs ₹11,005.88)
Cash Flow Statement (H1 FY26 in INR Lacs)
- Net Cash Flow from Operating Activities: (₹1,469.32)
- Net Cash Flow from Investing Activities: (₹1,091.25)
- Net Cash Flow from Financing Activities: ₹2,553.83
- Net Change in Cash & Equivalents: (₹6.75)
- Closing Cash Balance: ₹399.90 (vs Opening: ₹406.64)
Quarterly Standalone Performance (Q2 FY27)
- Revenue From Operations: ₹3,272.68
- Other Income: ₹92.97
- Total Income: ₹3,365.65
- Net Profit for Quarter: ₹657.83
- Basic EPS (Not Annualized): ₹5.50
Consolidated Financial Performance (H1 FY27)
Income Statement Highlights (INR Lacs)
- Revenue From Operations: ₹8,080.23
- Other Income: ₹154.12
- Total Income: ₹8,234.36
- Total Expenses: ₹6,693.14
- Profit Before Tax: ₹1,541.22
- Current Tax: ₹375.00
- Net Profit for Period: ₹1,166.22
- Minority Interest: ₹3.50
- Profit after Minority Interest: ₹1,162.72
- Basic EPS (Not Annualized): ₹9.72
- Diluted EPS (Not Annualized): ₹9.72
Consolidated Entities
The consolidated results include:
- Trident Lifeline Limited (Parent)
- TNS Pharma Private Limited (51% subsidiary, acquired December 21, 2022)
- TLL Parenterals Limited (51% subsidiary, acquired December 7, 2024)
- Trident Mediquip Limited (59.67% subsidiary, acquired July 4, 2025, with additional acquisitions)
- TLL Elements Private Limited (51% subsidiary, acquired April 15, 2024)
- TLL Wellness Limited (51% subsidiary, formerly TLL Herbal Limited, acquired August 10, 2023)
Balance Sheet Position (Consolidated, as of September 30, 2026 vs March 31, 2026 in INR Lacs)
- Total Equity and Liabilities: ₹25,317.57 (vs ₹23,682.90)
- Shareholder's Funds: ₹11,873.21 (vs ₹10,416.58)
- Share Capital: ₹1,195.70 (vs ₹1,193.30)
- Reserves & Surplus: ₹9,827.71 (vs ₹8,474.26)
- Minority Interest: ₹849.80 (vs ₹749.02)
- Non-Current Liabilities: ₹6,897.80 (vs ₹4,104.38)
- Current Liabilities: ₹6,189.84 (vs ₹4,789.27)
- Total Assets: ₹25,317.57 (vs ₹23,682.90)
Subsidiary Ownership Updates
- Trident Mediquip Limited: Increased holding to 59.67% through acquisitions of 9,64,875 shares between July 30, 2025-March 16, 2026, bonus issue, and additional 1,00,000 shares on September 29, 2026
- TNS Pharma Private Limited: Acquired 1,02,000 shares on November 16, 2025, maintaining 51% holding